Laurent Pharmaceuticals, Inc., a Montreal-based biopharmaceutical company, today announced the publication in the peer-reviewed Journal of Cystic Fibrosis of previously disclosed results from its Phase 2 study of LAU-7b for the treatment of Cystic Fibrosis (CF). The article, titled “Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis” details the study’s findings showing evidence of preservation of lung function that supports further development in CF.
